Researching Beauty

Together with EthiQ2, you’ll help bring the future of health and beauty to today’s patients.

EthiQ2 Medical Research Trials

We can’t wait to tell you about the research studies available at EthiQ2. Your interest and participation help us remain at the forefront of medical, surgical, and cosmetic techniques, devices, and medications while maintaining the highest standards expected of healthcare. Our research studies are conducted by board-certified surgeons who are dedicated to the future of health and beauty aesthetics, and by participating in our studies, you’ll help advance these upcoming progressive solutions while optimizing both the health of your skin and your overall appearance. Our studies are critical to the FDA, as they approve treatments and devices like topical medications, injectables, lasers, non-invasive procedures, and more. But as a patient of ours, there’s nothing to be afraid of. Safety is our top priority. The strict standards of each trial means your safety and health are assured while giving you access to the latest treatments and technologies. Currently, we are taking the extra safety measures to ensure you are safe from COVID-19 while visiting the clinic setting.

What to Expect

EthiQ2 has been conducting clinical trials in cosmetic, and surgical aesthetics for many years. Our dedication to the advancement of our field of aesthetics services, techniques, and technology helps others overcome their skin concerns and achieve their beauty goals. Health research also aims to find better ways to prevent and treat conditions and you can be a part of that advancement. Studies can last 1 – 12 months, sometimes longer. In participating, you may be required to visit our office weekly or monthly, be given or take the prescribed medication precisely as instructed, adhere to daily or weekly regimens, be photographed, fill out questionnaires, and sometimes keep a treatment journal. You’ll always be in the hands of caring professionals dedicated to your safety and health as we help develop products, therapies, and devices for the future.

Study Participants

Study Participates differ depending on the trial being conducted, but typically, if you’re in good health, are over the age of 18, not pregnant, and want to be part of advancing the future of medicine, you’re likely an ideal candidate. However, please be aware that each trial has distinct guidelines, such as strict participation criteria, and requires patients with very specific conditions. There is no guarantee at EthiQ2 that every individual subject who qualifies and wants to participate in a trial will be enrolled. Contact the Research Coordinator to discuss any study eligibility and potential participation.

About the Team

Dr. Andrew Campbell is an internationally renowned, double board-certified facial plastic and reconstructive surgeon specializing in facial rejuvenation. His post-graduation education included an internship at the University of Cincinnati General Surgery in 1994 and a residency at University of Cincinnati in 1998. In 2005, he founded Quintessa Aesthetic Center to satisfy his patient’s desires for non-surgical rejuvenation options. He was one of the first in the nation to offer Ultherapy, ThermiRF, Vanquish and Halo. In 2016, he opened a research facility to further his passionate commitment to advancing his field and thoroughly enjoys the collaboration with other experts bringing new ideas forward into the Aesthetic world. Dr. Campbell is a board member and examiner for the American Academy of Facial Plastic & Reconstructive Surgery, former chairman of the national Emerging Trends & Technologies Committee, Allergan injectable trainer for the Midwest, Luminary for Sciton Lasers in the Midwest, and supporter of the Face to Face charity organization.

Kelly has over 10 years of experience in various specialties ranging from in home nursing care, family practice, hospice care and cancer care. In 2013, she became the Lead RN for a family practice clinic at Aurora Health Center in WI where she took pride in providing the best care possible for patients within the community. She has a strong background in Case Management skills where she has worked in many different specialty areas and gained a great deal of knowledge alongside a strong work ethic. Kelly has a strong passion for helping people and providing cutting edge care solutions through aesthetic research. In 2017, she made the transition into Aesthetic Medicine applying her interests in aesthetic clinical research where she joined ETHIQ2 as an RN research study coordinator working under the direction of Dr. Andrew Campbell. This experience has shaped her passion for clinical research education in so many ways. At EthiQ2, our goals strive in giving the most advanced and innovative treatment options through critical advances in aesthetic medicine that can only happen with research and education.

Heidi has more than 30 years of experience in various medical specialty settings. Her passion for technology and beauty merged over 20 years ago when she started researching laser settings and skin response in a clinic office alongside her medical director and husband, Dr Andrew Campbell. It was the beginning of Medispa treatments before they really existed. Years of expanding laser technologies and improving skin outcomes for her patients continues to drive her to investing into clinical research studies. She values the relationships with her patients and the emerging devices that continue to succeed expectations. Heidi is Clinical Director at Quintessa and oversees training of staff to assure the highest quality standards of all of the providers while participating in clinical research studies at EthiQ2 to push the beauty industry towards better and better products and technologies.

Our Studies

Phase III Multicenter, Long Term, Open Label Study to Evaluate AGN-151586 for Glabellar Lines

Status: Ongoing

Compensation: Yes

An investigational product being developed for the treatment of glabellar (frown) lines. AGN-151586 offers the potential for faster onset of efficacy compared with the Botulinum Neurotoxin Serotype A (BoNT/A) products. The primary objective of this study is to evaluate the long-term safety of AGN-151586 after repeated cycles of study drug treatments over 12 months in subjects with moderate or severe frown lines.

Non-surgical tightening of face and neck

Status: Completed

Compensation: Yes
Evaluating the cellular changes associated with a non-invasive treatment to obtain lift and tightening of facial and neck tissue by utilizing an Ulthera System to deliver ultrasound energy in a focused manner below surface of the skin. Demonstrating the effectiveness in the improvement in overall lifting and tightening of skin. Biopsies were obtained during planned lower facelift procedures at a variety of time periods after the ultrasound treatment.

Investigational Drug for Gabellar Lines

Status: Completed

Compensation: Yes

A biotechnology company focused on innovative aesthetic offerings, evaluated a next generation investigational drug, a Neuromodular product, for injection in the treatment of dynamic glabellar (frown) lines. Evaluating the impact of dose efficacy and duration of effect (how long it took for treated areas to return back to baseline). Subjects were followed for a duration of 36 weeks and fully compensated for their time and cooperation in attending all follow up visits to assess overall satisfaction, safety and effectiveness/duration of areas treated.

A phase 2 multi-center study to evalutate the effectiveness and safety of a novel filler for the treatment of decolletage wrinkles

Status: Ongoing

Compensation: Yes

A randomized, evaluator-blinded, no-treatment controlled, multicenter study to evaluate the effectiveness and safety of GAL1906 for correction of wrinkles in the decolletage area.

Frown lines

Status: Completed

Compensation: Yes
A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines. AbobotulinumtoxinA is a prescription injection for temporary improvement in the look of moderate to severe frown lines in adults less than 65 years of age. Subjects were followed and evaluated for 9 months, looking at efficacy as well as duration of treatment response, subject satisfaction, aesthetic improvement and onset of treatment responses.

Frown lines and Crows feet

Status: Completed

Compensation: Yes

Evaluated the safety of an experimental Botulinum toxin for long term treatment of moderate to severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet). Eligible clients received up to 4 re-treatment’s and fully compensated for their commitment and needed cooperation in attending monthly follow up visits for up to 12 months.

Patient Sign Up

    Industry Sign Up